title: [Multiple sclerosis: can therapy delay ongoing disability?].
authors.affiliation: Institut für Klinische Neuroimmunologie, Klinikum der Universität München, Grosshadern, Ludwig-Maximilians-Universität München. joachim.havla@med.lmu.de
authors.forename: Joachim
authors.initials: J
authors.lastname: Havla
authors.forename: Hannah L
authors.initials: HL
authors.lastname: Pellkofer
authors.forename: Reinhard
authors.initials: R
authors.lastname: Hohlfeld
authors.forename: Tanja
authors.initials: T
authors.lastname: Kümpfel
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000187:drug effects / Q000473:pathology; D004185:Disability Evaluation; D018450:Disease Progression; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000145:classification / Q000175:diagnosis / Q000523:psychology / Q000534:rehabilitation*; D000069442:Natalizumab; D009460:Neurologic Examination / Q000187:drug effects; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011788:Quality of Life / Q000523:psychology; D014910:Wheelchairs
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D018696:Neuroprotective Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons